ISIN.net news update announces 6 month results:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces its half year results for the six months ended 30 June 2015.
Main operational highlights:
Post period end main highlights:
Laurent Levy, Chief Executive Officer and co-founder of Nanobiotix, said:
“We have made significant advances in the last six months, particularly in the clinical development of our lead NanoXray product, NBTXR3. We are now running clinical trials in five indications: soft tissue sarcoma, head and neck cancer, rectal cancer (by PharmaEngine) and liver cancers (primary and metastatic). This demonstrates the potential transferability of NBTXR3 to be used across different types of cancers. We will continue to expand NBTXR3 clinical development by launching other indications such as prostate cancer, expected in the US by the end of the year. Nanobiotix’s financial position remains strong and in line with the Company’s expectations. We look forward to the productive coming months for our clinical development and remain on track to achieve a CE mark for our lead product in soft tissue sarcoma in late 2016.”
CEO’s Operational Report
There have been significant developments in a number of clinical trials running for NBTXR3 in the first six months of the year. The Company’s clinical developments exceeded expectations and expenses were kept in line with the planned budget. The key highlights of the period are summarised below.
Nanobiotix is a pioneer in nanomedicine, developing a first-in-class proprietary technology called NanoXray. Nanobiotix’ strategy is to establish a pipeline of products as cancer nanomedicine reference points in the oncology markets.
For the entire release, please click here